Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing. The round was ...

1亿美元助力创新分子胶降解剂开发Neomorph是一家致力于开发分子胶降解剂以靶向此前被认为“不可成药”蛋白的生物技术公司。该公司今日宣布完成1亿美元B轮融资。本轮融资所得资金将主要用于推进在研疗法NEO-811的1/2期临床试验。该研究是一项首次人 ...

Presentation in the New Drugs on the Horizon session to feature the development of NEO-811, a novel ARNT (HIF-1β)-targeted therapy in clear cell ...

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...

Neomorph是一家美国蛋白质降解剂研发商，公司正在建立一个蛋白质降解实体，专注于“分子胶”降解剂。靶向蛋白质降解为在包括肿瘤学在内的各种疾病领域开发新型疗法提供了机会。近日，Neomorph宣布完成了1亿美元的B轮融资。本轮融资由Deerfield Management领投，新投资者包括Regeneron Ventures、Longwood ...

Neomorph公司日前宣布，已与诺和诺德（Novo Nordisk）达成合作与许可协议，共同发现、开发和商业化分子胶蛋白降解剂。Neomorph是一家通过发现针对“不可成药”靶点的创新疗法来解决人类健康问题的生物技术公司，成立于2020年，由Deerfield Management Company支持。

San Diego startup Neomorph on Monday announced a new $100 million investment for its molecular glue that tricks cancer cells into self-destructing. Even as it awaits results from its first clinical ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management ...

AbbVie has completed the acquisition of Nimble Therapeutics. Credit: © AbbVie Inc. All rights reserved. · Pharmaceutical Technology · © AbbVie Inc. All rights ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...